Sign up to our newsletter Subscribe
Understanding societal preferences for priority by disease severity in England & Wales
< 1 min read|01/06/2012
Is There a Productivity Crisis in Pharmaceutical R&D?
This Seminar Briefing recounts the key points made by Prof Riccaboni, from the University of Trento, at a recent OHE Lunchtime Seminar. It focuses primarily on the reasons for a decline since 2000 in the average number of new drugs launched per year…
This Seminar Briefing recounts the key points made by Prof Riccaboni, from the University of Trento, at a recent OHE Lunchtime Seminar. It focuses primarily on the reasons for a decline since 2000 in the average number of new drugs launched per year by the pharmaceutical industry. Factors identified as important include a trend towards targeting more complex and difficult diseases, the need to adapt to dramatic changes in scientific knowledge and in R&D approaches, and substantial changes in both the regulatory and marketing climates.
In addition to describing overall trends, Prof Riccaboni also compares the R&D performance of companies based in the US and Europe, and a set of “global” companies. He finds that the global companies rank highest on R&D productivity and equal US companies in the market value of their new drugs.
Is There a Productivity Crisis in Pharmaceutical R&D?
Riccaboni, M. (2012) Is There a Productivity Crisis in Pharmaceutical R&D?.
OHE Seminar Briefing. Available from https://www.ohe.org/publications/there-productivity-crisis-pharmaceutical-rd/
